Hepatitis A and B Booster Vaccination Guidelines

Introduction to Booster Recommendations

• The CDC Advisory Committee on Immunization Practices emphasizes that immune memory, rather than circulating antibody levels, is the key determinant of long-term protection against clinical disease 1
• Healthy individuals who responded to the complete primary vaccination series do not require routine booster doses, as immune memory persists even when antibody levels decline below detectable levels 1

Special Populations Requiring Boosters

• Hemodialysis patients should receive annual anti-HBs testing and a booster dose when anti-HBs levels decline below 10 mIU/mL 1
• Healthcare personnel with anti-HBs <10 mIU/mL after primary vaccination should receive one additional dose of hepatitis B vaccine, and if anti-HBs remains <10 mIU/mL after the additional dose, complete a second 3-dose series 1
• Immunocompromised individuals should consider annual anti-HBs testing if ongoing risk for exposure exists and receive boosters when levels fall below 10 mIU/mL 1

Non-Responders to Primary Series

• Persons with anti-HBs <10 mIU/mL after the primary vaccine series should be revaccinated with a complete 3-dose series 2
• Retest anti-HBs 1-2 months after the third dose, and if still non-responsive, test for HBsAg and HBc to rule out chronic infection 3

Postexposure Prophylaxis Considerations

• If written documentation of complete hepatitis B vaccine series exists but no postvaccination testing was performed, administer a single vaccine booster dose after HBsAg-positive exposure 2, 3
• No booster is needed for persons with documented serologic response (anti-HBs ≥10 mIU/mL) 4

Interrupted Vaccination Schedules

• If the hepatitis B vaccination schedule is interrupted, do not restart the series—simply administer the remaining doses as soon as possible 5

Common Pitfalls to Avoid

• Do not administer unnecessary boosters to healthy individuals who completed the primary series, as this is not supported by evidence and wastes resources 1
• Do not rely solely on antibody levels in immunocompetent individuals—immune memory persists even when anti-HBs is undetectable 1
• Do not overlook post-vaccination serologic testing in high-risk groups (healthcare workers, hemodialysis patients, immunocompromised individuals) to confirm initial response 1
• Do not forget annual monitoring for hemodialysis patients and other specified high-risk groups, as they require ongoing surveillance 1

Hepatitis B Vaccination Series Completion

General Management Principle

• The Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) recommends that if the hepatitis B vaccination series is interrupted, the series does not need to be restarted—simply administer the next dose as soon as possible 6
• Previously administered doses remain valid and immune system memory continues 6

Accelerated Vaccination Program Interruption

• If the accelerated vaccination program (0-1-2 months or 0-7-21 days) is interrupted, complete the remaining doses at standard minimum intervals 6
• The minimum interval between the first two doses should be 4 weeks 6
• The minimum interval between the second and third doses should be 8 weeks 6
• The minimum interval between the first and third doses should be 16 weeks 6

Special Approach in Exposure Situations

• If a patient who has not completed the vaccination series is exposed to an HBsAg-positive source, administer both HBIG (hepatit B immunoglobulin) and continue the vaccination series 7, 6, 8
• HBIG should be administered as soon as possible (preferably within 24 hours) after exposure 7, 6, 8
• HBIG and vaccine can be administered simultaneously in different anatomical regions (e.g., different arms) 6, 8
• There is no need to restart the vaccination series to complete it 7, 6, 8

Post-Vaccination Test Recommendations

• After completing the vaccination series, an anti-HBs test should be performed 1-2 months after the last dose 6, 9
• A protective level of anti-HBs is ≥10 mIU/mL 6, 9
• This test is particularly important for healthcare workers, hemodialysis patients, and immunosuppressed patients 6, 9

Approach for Non-Responders

• If anti-HBs <10 mIU/mL after a complete series, a second complete series of 3 doses should be administered 9
• If still non-responsive after the second series, HBsAg and anti-HBc tests should be performed to rule out chronic infection 9
• For non-responders after two complete series, 2 doses of HBIG are required for future exposures 9

Management of Hepatitis B Vaccine Non-Responders

Initial Management After Non-Response to Booster

• The Centers for Disease Control and Prevention recommends administering a full 3-dose revaccination series using the standard schedule (0, 1, and 6 months) for patients who do not respond to a hepatitis B booster 10, 11
• Between 25-50% of non-responders will respond to a single additional dose, while 44-100% respond to a complete 3-dose revaccination series 11
• Retest anti-HBs levels 1-2 months after completing the third dose of the revaccination series 10

Testing After Revaccination

• If anti-HBs remains <10 mIU/mL after revaccination, test for HBsAg and anti-HBc to rule out chronic HBV infection, as recommended by the Centers for Disease Control and Prevention 10
• Persons who test HBsAg-positive require appropriate management for chronic hepatitis B 10

Management of Confirmed Non-Responders

• Counsel the patient that they are susceptible to HBV infection and require HBIG for any known exposure, as advised by the Centers for Disease Control and Prevention 10
• Document non-responder status clearly in the medical record 10
• For future HBsAg-positive exposures, administer HBIG (0.06 mL/kg) as soon as possible, preferably within 24 hours 10

Special Population Considerations

• Modified dosing regimens with doubled antigen doses or additional doses may increase response rates in immunocompromised patients, such as HIV-infected persons, hemodialysis patients, and transplant recipients 10, 11
• These patients have reduced humoral response and may require more aggressive revaccination protocols 11

Critical Pitfalls to Avoid

• Do not assume a patient is a non-responder without confirming they completed the full primary series with appropriate intervals (minimum 4 weeks between doses 1 and 2, 8 weeks between doses 2 and 3, and 16 weeks between doses 1 and 3), as stated by the Centers for Disease Control and Prevention 11
• Genetic factors may contribute to non-response, and some individuals will never mount an adequate antibody response despite multiple vaccination attempts 11

Hepatitis B Vaccine Non-Responders: Revaccination Strategy

Initial Management Approach

• If an individual remains non-responsive to the hepatitis B vaccine after a single booster dose, they should complete a full 3-dose revaccination series, as recommended by the CDC Advisory Committee on Immunization Practices 12, 13

Management of Confirmed Non-Responders

• If an individual remains non-responsive after two complete 3-dose series (6 total doses), no additional vaccine doses are recommended, and they will require 2 doses of HBIG (hepatitis B immune globulin) if exposed to an HBsAg-positive source, with the first dose given as soon as possible after exposure and the second dose 1 month later 12, 13
• For healthcare workers and high-risk individuals, documented antibody levels ≥10 mIU/mL remain the standard for confirming protection, as recommended by the CDC Advisory Committee on Immunization Practices 12, 13

Important Considerations

• The CDC Advisory Committee on Immunization Practices recommends that individuals who remain non-responsive after revaccination should not receive more than 6 total doses (two complete 3-dose series), as additional doses beyond this are not recommended and won't help 12, 13